The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
ACADEMIA
Antimicrobial Use in 2021 Down 31.5% from 2013: Expert
The consumption of antimicrobial drugs in Japan worked out based on sales volume stood at 10.21 DID (defined daily dose/1,000 inhabitants/day) in 2021, down 31.5% compared to 2013, according to an expert. The data was presented by Shinya Tsuzuki, director…
To read the full story
ACADEMIA
- Japan Obesity Society Urges Attention to Suicidal Thoughts in Patients Who Use Wegovy
November 29, 2023
- Scientific Societies Urge Greater Caution for COVID Drug Use in Women of Childbearing Age
November 15, 2023
- Chemotherapy Society Urges Govt to Create Body to Spur Drug Discovery
October 31, 2023
- G1 Product Info Could Disappear after Withdrawal, PMDA Website Should Retain Posting: Pharmacist
October 11, 2023
- Flu Drug Spending Hits 48 Billion Yen in FY2017, NCGM Flags Cost-Effectiveness
October 10, 2023
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…